Moonbase
← Back to Funding Opportunities
Grants.govDefense Health Agency Contracting Activity - DHACA

DoW Neurofibromatosis Research Academy – Scholar Award

Posted Jun 25, 2026·open

AGENCY

DOD-AMRAA

PROGRAM

Discretionary

AMOUNT

CLOSES

Sep 22, 2026

Description

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy – Scholar Award (NFRA-SA) supports early-career independent investigators (Scholars) joining the Neurofibromatosis Research Academy to pursue a neurofibromatosis project that may include basic, translational, and/or clinical research. The proposed research should address at least one of the FY26 NFRP Areas of Emphasis, under the leadership of the NFRA Director and Deputy Director. The overarching goal of the NFRA is to conduct innovative and impactful research in the field of neurofibromatosis disorders while developing successful, highly productive NF researchers in a collaborative research and career development environment.


Distinctive Features:

• Scholar: The Scholar, named as the Principal Investigator, must be less than 10 years of completion of their terminal degree by the time of the application deadline (excluding time spent in residency, clinical training, or on family medical leave).

• Career Guide: This award mechanism requires each Scholar to designate a Career Guide for guidance. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, the application must identify a secondary Career Guide at the Scholar’s institution.

Eligibility

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Contact

Ebony S Simmons Grantor

help@eBRAP.org

301-619-2105

Additional details

Funding instrument
Grant
Cost sharing required
No
Archived
Oct 22, 2026

Opportunity number: HT942526NFRPNFRASA

Search this number on Grants.gov for the official listing.